uniQure advances gene therapy AMT-130 for Huntington’s, plans UK submission and FDA talks in 2026

uniQure reported Q1 2026 financial results and progress on its gene therapy pipeline, notably AMT-130 for Huntington’s disease. The company plans a UK Marketing Authorization Application submission in Q3 2026 after positive MHRA feedback and will discuss new clinical trial designs with the FDA in Q2. Clinical updates for AMT-260 epilepsy and AMT-130 four-year data are expected later in 2026. uniQure holds $586.6 million cash, funding operations into late 2029, supporting ongoing development and regulatory efforts.